Efficacy and Safety of Degarelix One Month Dosing Regimen in Korean Patients With Prostate Cancer

NCT01071915 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

157

Enrollment

INDUSTRY

Sponsor class

Conditions

Prostate Cancer

Interventions

DRUG: Degarelix 240/80 mg

Sponsor

Ferring Pharmaceuticals

Collaborators

[object Object]